Molbio Diagnostics shares surged 20% on September 10, 2026, reaching an all-time high of ₹1,509.70. This jump marks an 87% increase from its initial public offering (IPO) price. The company reported a profit of ₹52.74 crore for the first quarter of fiscal year 2027, driven by a sharp rise in volumes of its Truenat test kits, according to livemint.com.
The share price rally followed the release of the company’s quarterly financial results, which showed strong growth in demand for its diagnostic products. Molbio Diagnostics’ Truenat test kits, used widely for infectious disease detection, saw a significant volume increase, reinforcing investor confidence. The company’s robust earnings and market position contributed to the stock hitting the upper circuit limit on the trading day.
Molbio Diagnostics’ performance highlights the rising investor interest in healthcare diagnostics amid growing demand for advanced testing solutions in India. The company’s IPO was well received, and the current price surge reflects its expanding market footprint. Compared to other recent healthcare listings, Molbio’s stock performance stands out for its rapid appreciation post-IPO, underscoring the sector’s potential.
Molbio Diagnostics’ next financial update is expected with the release of its half-yearly results, which will provide further insights into its growth trajectory. The stock’s strong performance on September 10, 2026, positions it as one of the notable gainers in the Indian healthcare diagnostics segment this year.